耳鼻咽喉科・頭頸部外科90巻10号

2018年09月発行

特集 どこが変わった頭頸部癌診療ガイドライン

がん薬物療法

著者： 清田尚臣¹

所属機関： ¹神戸大学医学部附属病院腫瘍センター

ページ範囲：P.855 - P.860

文献概要

POINT

●プラチナ抵抗性頭頸部扁平上皮癌に対する免疫チェックポイント阻害薬，また甲状腺癌に対する血管内皮成長因子受容体（VEGF-R）を標的とする分子標的薬が登場し，頭頸部癌領域の臨床は大きく変わった。

●これらの薬剤の登場により治療オプションは増えたが，有害事象への対応などがん薬物療法はますます複雑化している。

●ガイドラインでは治療総論に「がん薬物療法」が新設され，治療目標を①根治を目指した集学的治療，②再発・転移に対する化学療法，に分けて解説されている。クリニカルクエスチョン（CQ）でも変更点や新規CQが加わっている。

参考文献

1）Ferris RL, et al：Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375：1856-1867, 2016

2）Kiyota N, et al：A randomized, open-label, Phase Ⅲ clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck：a subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncol 73：138-146, 2017

3）Brose MS, et al：Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer：a randomised, double-blind, phase 3 trial. Lancet 384：319-328, 2014

4）Schlumberger M, et al：Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372：621-630, 2015

5）Wells SA, Jr., et al：Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer：a randomized, double-blind phase Ⅲ trial. J Clin Oncol 30：134-141, 2012

6）Kiyota N, et al：Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 106：1714-1721, 2015

7）Tahara M, et al：Lenvatinib for anaplastic thyroid cancer. Front Oncol 7：25, 2017

8）Ito Y, et al：Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid 27：1142-1148, 2017

9）Sun Y, et al：Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma：a phase 3, multicentre, randomised controlled trial. Lancet Oncol 17：1509-1520, 2016

10）Blanchard P, et al：Chemotherapy and radiotherapy in nasopharyngeal carcinoma：an update of the MAC-NPC meta-analysis. Lancet Oncol 16：645-655, 2015

11）Ribassin-Majed L, et al：What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 35：498-505, 2017

12）Elisei R, et al：Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31：3639-3646, 2013

13）Schlumberger M, et al：A phase Ⅱ trial of the multitargeted tyrosine kinase inhibitor lenvatinib（E7080）in advanced medullary thyroid cancer. Clin Cancer Res 22：44-53, 2016

14）Ha HT, et al：A phase Ⅱ study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20：975-980, 2010

15）Savvides P, et al：Phase Ⅱ trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 23：600-604, 2013

16）Bible KC, et al：A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 97：3179-3184, 2012

17）Licitra L, et al：Cisplatin in advanced salivary gland carcinoma. A phase Ⅱ study of 25 patients. Cancer 68：1874-1877, 1991

18）Airoldi M, et al：Phase Ⅱ randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91：541-547, 2001

19）Gilbert J, et al：Phase Ⅱ trial of taxol in salivary gland malignancies（E1394）：a trial of the Eastern Cooperative Oncology Group. Head Neck 28：197-204, 2006

20）Licitra L, et al：Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase Ⅱ trial of 22 patients. Ann Oncol 7：640-642, 1996

21）Haddad R, et al：Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase Ⅱ study. Oral Oncol 39：724-727, 2003

22）Limaye SA, et al：Trastuzumab for the treatment of salivary duct carcinoma. Oncologist 18：294-300, 2013

23）Jaspers HC, et al：Androgen receptor-positive salivary duct carcinoma：a disease entity with promising new treatment options. J Clin Oncol 29：e473-476, 2011

24）Locati LD, et al：Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck 38：724-731, 2016

25）Forastiere AA, et al：Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349：2091-2098, 2003

26）Pignon JP, et al：Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma：three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355：949-955, 2000

27）Pignon JP, et al：Meta-analysis of chemotherapy in head and neck cancer（MACH-NC）：an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92：4-14, 2009

28）Wolf GT, et al；Department of Veterans Affairs Laryngeal Cancer Study Group：Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324：1685-1690, 1991

29）Lefebvre JL, et al：Larynx preservation in pyriform sinus cancer：preliminary results of a European Organization for Research and Treatment of Cancer phase Ⅲ trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88：890-899, 1996

30）Pointreau Y, et al：Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101：498-506, 2009

31）Posner MR, et al：Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357：1705-1715, 2007

32）Vermorken JB, et al：Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357：1695-1704, 2007

33）Machtay M, et al：Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer：an RTOG analysis. J Clin Oncol 26：3582-3589, 2008

34）Forastiere AA, et al：Long-term results of RTOG 91-11：a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31：845-852, 2013

35）Adelstein DJ, et al：An intergroup phase Ⅲ comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21：92-98, 2003

36）Blanchard P, et al：Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers：an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 31：2854-2860, 2013

37）Cohen EE, et al：Phase Ⅲ randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 32：2735-2743, 2014

38）Hitt R, et al：A randomized phase Ⅲ trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25：216-225, 2014

39）Haddad R, et al：Induction chemotherapy followed by concurrent chemoradiotherapy（sequential chemoradiotherapy）versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer（PARADIGM）：a randomised phase 3 trial. Lancet Oncol 14：257-264, 2013

40）Ghi MG, et al：Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase Ⅱ-Ⅲ trial. Ann Oncol 28：2206-2212, 2017

41）Lazarev S, et al：Mucosal melanoma of the head and neck：a systematic review of the literature. Int J Radiat Oncol Biol Phys 90：1108-1118, 2014

42）Lopez F, et al：Update on primary head and neck mucosal melanoma. Head Neck 38：147-155, 2016

43）Shiga K, et al：Malignant melanoma of the head and neck：a multi-institutional retrospective analysis of cases in northern Japan. Head Neck 34：1537-1541, 2012

44）D'Angelo SP, et al：Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma：a pooled analysis. J Clin Oncol 35：226-235, 2017

45）Shoushtari AN, et al：The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 122：3354-3362, 2016

46）Cohen EE, et al：Pembrolizumab（pembro）vs standard of care（SOC）for recurrent or metastatic head and neck squamous cell carcinoma（R/M HNSCC）：Phase 3 KEYNOTE-040 trial. Ann Oncol 28（suppl 5）, 2017